US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

WisdomTree Asia Local Debt Fund

44.39

0.0000

Volume:- -

Turnover:- -

Market Cap:22.20M

PE:16.75

High:44.39

Open:44.39

Low:44.39

Close:44.39

Loading ...

Overview Company News Filings

Adisyn Subsidiary Installs New Atomic Layer Deposition System at Israeli Research Centre

Adisyn Ltd Advances Graphene Research with New ALD System

Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Ampol Limited's (ASX:ALD) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Simply Wall St.

Adisyn Confirms Delivery of Deposition System; Shares Rise 7%

MT Newswires Live

Press Release: GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

Press Release: Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results

Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment

Investors Aren't Buying Ampol Limited's (ASX:ALD) Revenues

Simply Wall St.

Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment

Lightwave Logic Announces Controlled Availability of Silicon Photonics Process Design Kit for Advanced Electro-Optic Polymer Integration

ACCESS Newswire

Closing Bell: Tech tumble and Trump tariffs trample Thursday

TSMC’s big US bet and China’s chip tool challenger

Financial Times

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy

Ampol Limited (ASX:ALD) is favoured by institutional owners who hold 51% of the company

Simply Wall St.

Ampol's (ASX:ALD) Shareholders Will Receive A Smaller Dividend Than Last Year

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","market":"US","secType":"STK","nameCN":"WisdomTree Asia Local Debt Fund","latestPrice":44.39,"timestamp":1567195200000,"preClose":44.39,"halted":0,"volume":0,"delay":0,"floatShares":400000,"shares":500000,"eps":2.65,"marketStatus":"Market Closed","change":0,"latestTime":"08-30 16:00:00 EDT","open":44.39,"high":44.39,"low":44.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":2.65,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":44.39,"sharesOutstanding":400000,"nav":44.492139,"aum":17756473.36,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0,"high":44.39,"amplitude":0,"preClose":44.39,"low":44.39,"week52Low":41.78,"pbRate":"--","week52High":46.6477,"institutionHeld":0,"latestPrice":44.39,"eps":2.65,"divideRate":0,"volume":0,"delay":0,"ttmEps":2.65,"open":44.39,"prevYearClose":44.39},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552210850","title":"Adisyn Subsidiary Installs New Atomic Layer Deposition System at Israeli Research Centre","url":"https://stock-news.laohu8.com/highlight/detail?id=2552210850","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552210850?lang=en_us&edition=fundamental","pubTime":"2025-07-17 12:40","pubTimestamp":1752727244,"startTime":"0","endTime":"0","summary":"Adisyn  subsidiary 2D Generation has completed the installation, commissioning and calibration of a Beneq TFS 200 atomic layer deposition  system at Israel’s Jan Koum Centre for Nanoscience and Nanotechnology.The project follows substantial infrastructure works at the centre including an upgrade to the environmental control systems and high-specification electrical works that support the precision demands of ALD-based research.ALD machines are used at the majority of the world’s semiconductor fabrication facilities to deposit extremely thin layers  of material on to chips.The Beneq TFS 200 model has customised features including plasma options for wafer surface treatments and potential introduction of reactive gases that catalyse graphene growth, semi-automatic load and lock enabling room temperature sample exchange and reduced heating and cooling times, and a reaction chamber suitable for wafer-scale processing.These capabilities are essential for advancing the proprietary low-tempera","market":"nz","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/07/featured-1752727135676.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/07/featured-1752727135676.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/adisyn-subsidiary-atomic-layer-deposition-system-israeli-research-centre/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7043","ALD.AU","ALD","BK7065","AI1.AU"],"gpt_icon":0},{"id":"2552175158","title":"Adisyn Ltd Advances Graphene Research with New ALD System","url":"https://stock-news.laohu8.com/highlight/detail?id=2552175158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552175158?lang=en_us&edition=fundamental","pubTime":"2025-07-17 06:47","pubTimestamp":1752706035,"startTime":"0","endTime":"0","summary":"The latest announcement is out from DC Two Ltd. ( ($AU:AI1) ). Adisyn Ltd has successfully commissioned a new Atomic Layer Deposition (ALD) system ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adisyn-ltd-advances-graphene-research-with-new-ald-system?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adisyn-ltd-advances-graphene-research-with-new-ald-system?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"gpt_icon":0},{"id":"2550968647","title":"Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2550968647","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550968647?lang=en_us&edition=fundamental","pubTime":"2025-07-12 00:26","pubTimestamp":1752251174,"startTime":"0","endTime":"0","summary":"Altimmune (($ALT)) announced an update on their ongoing clinical study. Altimmune, Inc. is currently conducting the RESTORE TRIAL, a Phase 2 study ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/altimmunes-restore-trial-a-promising-step-in-ald-treatment-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/altimmunes-restore-trial-a-promising-step-in-ald-treatment-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"gpt_icon":0},{"id":"2550341326","title":"Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550341326","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550341326?lang=en_us&edition=fundamental","pubTime":"2025-07-09 19:30","pubTimestamp":1752060600,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., July  09, 2025  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiome","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112467/0/en/Altimmune-Announces-Initiation-of-RESTORE-Phase-2-Trial-Evaluating-the-Efficacy-and-Safety-of-Pemvidutide-in-Alcohol-Associated-Liver-Disease-ALD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1559883803.SGD","LU1242518857.USD","ALD","LU0566484027.USD","BK4588","LU1242518931.SGD","LU0979878070.USD","LU0053671581.USD","ELF","BK4183"],"gpt_icon":0},{"id":"2549406312","title":"Ampol Limited's (ASX:ALD) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?","url":"https://stock-news.laohu8.com/highlight/detail?id=2549406312","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549406312?lang=en_us&edition=fundamental","pubTime":"2025-07-05 07:02","pubTimestamp":1751670176,"startTime":"0","endTime":"0","summary":"Most readers would already be aware that Ampol's (ASX:ALD) stock increased significantly by 14% over the past three...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-limiteds-asxald-stock-has-seen-strong-momentum-does-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALD","ALD.AU","BK7065"],"gpt_icon":0},{"id":"2542363508","title":"Adisyn Confirms Delivery of Deposition System; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542363508","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542363508?lang=en_us&edition=fundamental","pubTime":"2025-06-10 11:15","pubTimestamp":1749525314,"startTime":"0","endTime":"0","summary":"Adisyn  confirmed the delivery of an atomic layer deposition  system to its subsidiary, 2D Generation, as part of plans to commercialize its low-temperature ALD graphene technology, according to a Tuesday filing with the Australian bourse.The company paid Beneq, the manufacturer, AU$600,000 upon delivery, with AU$150,000 payable upon commissioning of the system, the filing said.The system will undergo installation and commissioning, including calibration, test cycles, and integration into the upgraded infrastructure, per the filing.Shares rose 7% in midday trade on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7043","ALD.AU","ALD","BK7065","AI1.AU"],"gpt_icon":0},{"id":"2535174960","title":"Press Release: GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535174960","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535174960?lang=en_us&edition=fundamental","pubTime":"2025-05-14 17:28","pubTimestamp":1747214880,"startTime":"0","endTime":"0","summary":"GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease . -- Affecting up to 5% of the global population, SLD represents an area of. significant unmet medical need with limited treatment options. -- Phase II data show potential of efimosfermin to reverse liver fibrosis,-- Unique properties offer potential for efimosfermin to be a new. -- Significantly expands GSK's hepatology pipeline aimed at addressing. steatotic and viral drivers of liver disease, offering multiple. development options and potential first launch in 2029. GSK plc  and Boston Pharmaceuticals, a leading clinical. entered into an agreement under which GSK will acquire Boston. to treat and prevent progression of steatotic liver disease . Under. the agreement, GSK will pay $1.2 billion upfront, with potential for. both forms of SLD. Given efimosfermin's direct antifibrotic mechanism of. action and GSK's data-driven insights from ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","BK4588","BK4007","GSK.UK","III","LU1829250122.USD","GSK","ALD","BK4585","BK4532"],"gpt_icon":0},{"id":"2535265647","title":"Press Release: Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2535265647","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535265647?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:00","pubTimestamp":1747134000,"startTime":"0","endTime":"0","summary":"Term loan adds balance sheet strength and provides financial flexibility to support continued development of pemvidutide. Under the terms of the agreement, $15 million will be drawn at closing. An additional $25 million is available in 2025 at Altimmune's option, subject to certain clinical and financial milestones. The remaining $60 million is available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to the approval of Hercules. The facility is structured as interest only for the first 24 months, extendable up to 42 months on achievement of milestones. The loan matures 48 months from closing, and no warrants are included in the agreement.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","LU1878469433.USD","BK4232","R","BK4139","BK4135","BK4599","ALD","ALT","HTGC"],"gpt_icon":0},{"id":"2532076342","title":"Altimmune to Present at Upcoming EASL International Liver Congress™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532076342","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532076342?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:30","pubTimestamp":1746099000,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., May 01, 2025  -- Altimmune, Inc. , a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease  utilizing the MASH Resolution Index , a highly sensitive non-invasive measure of MASH histologic response, in a poster session at the European Association for the Study of the Liver  International Liver Congress 2025 in Amsterdam, The Netherlands. The abstract will be featured in the conference poster session and poster tour.Session: MASLD: Therapy, Track Hub 7 – Metabolism, Alcohol, and Toxicity . A copy of the poster will be accessible on the Events section of the Altimmune website.About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/altimmune-present-upcoming-easl-international-113000683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","BK4139","LU1878469433.USD","BK4599","ALD"],"gpt_icon":0},{"id":"2528221425","title":"Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2528221425","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528221425?lang=en_us&edition=fundamental","pubTime":"2025-04-17 00:03","pubTimestamp":1744819380,"startTime":"0","endTime":"0","summary":"Non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025 resulted in an adverse and uncertain situation regarding the continuation of the Company’s activities. Event of default triggered by this non-adoption under the financing agreements with IRIS and IPF Partners, allowing each of them to request immediate redemption of the outstanding bonds they hold . With a cash position of EUR 2 million as of March 31, 2025, the Company is unable to repay IRIS and IPF Partners if they redeem their outstanding bonds, which significantly compromises its ability to continue as a going concern. Pending the outcome of ongoing negotiations with its creditors, the Company postpones the approval and release of its 2024 annual accounts. POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-provides-financial-first-quarter-160300868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PXXLF","ALD"],"gpt_icon":0},{"id":"2526739848","title":"Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526739848","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526739848?lang=en_us&edition=fundamental","pubTime":"2025-04-09 00:11","pubTimestamp":1744128660,"startTime":"0","endTime":"0","summary":"Approval by the Pharmaceuticals and Medical Devices Agency  in Japan enables TWYMEEG  to be prescribed to type-2 diabetic patients with moderate to severe renal impairment. This approval is based on the results of the Phase 4 TWINKLE study. Sumitomo Pharma to immediately start promoting the use of the product in this new patient population, further supporting efforts to maximize TWYMEEG opportunity in Japan. This regulatory milestone could also support Poxel’s strategy and ongoing discussions to develop and commercialize Imeglimin outside of Japan. POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today announces that the Pharmaceuticals and Medical Devices Agency  in Japan has approved the revision of TWYMEEG package insert for patients with renal impairment with eGFR  less than 45 mL/min/1.73m2.This","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-regulatory-approval-japanese-161100485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALD","BK4139","PXXLF"],"gpt_icon":0},{"id":"2524474723","title":"Investors Aren't Buying Ampol Limited's (ASX:ALD) Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2524474723","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524474723?lang=en_us&edition=fundamental","pubTime":"2025-04-03 07:01","pubTimestamp":1743634883,"startTime":"0","endTime":"0","summary":"You may think that with a price-to-sales (or \"P/S\") ratio of 0.2x Ampol Limited ( ASX:ALD ) is definitely a stock worth...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/investors-arent-buying-ampol-limiteds-asxald-revenues","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALD.AU","ALD","ISBC"],"gpt_icon":0},{"id":"2523570219","title":"Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2523570219","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523570219?lang=en_us&edition=fundamental","pubTime":"2025-03-31 13:00","pubTimestamp":1743397200,"startTime":"0","endTime":"0","summary":"Newly granted patent covers Imeglimin’s use in type-2 diabetic patients with renal impairment and has a patent term in Japan until 2039. This patent further supports Poxel’s strategy to maximize Imeglimin’s commercial potential in Japan and beyond. POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare metabolic disorders, today announced that the Japanese Patent Office has granted Poxel a new patent  covering the use of Imeglimin in type-2 diabetic patients with moderate to severe renal impairment until 2039.Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis  and rare disorders. For the treatment of MASH, PXL065  met its primary endpoint in a streamlined Phase 2 trial . In r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-grant-patent-japan-050000749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALD","PXXLF","BK4139"],"gpt_icon":0},{"id":"2522574597","title":"Lightwave Logic Announces Controlled Availability of Silicon Photonics Process Design Kit for Advanced Electro-Optic Polymer Integration","url":"https://stock-news.laohu8.com/highlight/detail?id=2522574597","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522574597?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:30","pubTimestamp":1743165000,"startTime":"0","endTime":"0","summary":"Management team to attend the Optical Fiber Conference in San Francisco. DENVER, COLORADO / ACCESS Newswire / March 28, 2025 / Lightwave Logic, Inc.  , a technology platform company leveraging its proprietary electro-optic  polymers to transmit data at higher speeds with less power, today announced the controlled availability of its cutting-edge Process Design Kit . This PDK enables the integration of the Company's advanced EO polymers into Silicon Photonic Integrated Circuits  using Lightwave Logic's novel Back-End-of-Line  process.Despite the significant advancements in silicon photonics, scaling up to data rates of 200Gbps and 400Gbps presents inherent challenges. Traditional silicon photonics-based modulators face bandwidth limitations due to their reliance on charge-carrier effects, leading to increased power consumption and signal degradation at higher speeds. As data center and AI-driven networking demands continue to push for greater bandwidth efficiency, alternative materials ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lightwave-logic-announces-controlled-availability-123000669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4148","LWLG","BK4157","IE00B7SZL793.SGD","IE00B66KJ199.SGD","IE0031619046.USD","ALD","IE00B19Z4B17.USD","AEIS"],"gpt_icon":0},{"id":"2522775321","title":"Closing Bell: Tech tumble and Trump tariffs trample Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2522775321","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522775321?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:37","pubTimestamp":1743061048,"startTime":"0","endTime":"0","summary":"Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday. Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too. to quickly recap, tech stocks took a pounding today on the back of a Wall Street dump across the sector, with AI behemoth Nvidia leading losses with a 6% stumble.According to reports, fears around the company’s business in China sent investors into a bit of a tizz, after the White House added several Chinese companies to a trade blacklist.Per a report in The Australian:The US has added dozens of Chinese companies to a trade blacklist over national security concerns. American businesses seeking to sell technology to these companies will need approval from the government.One of those companies blacklisted is Inspur Group – China’s largest server maker and one of the key Chinese customers of Nvidia.The Trump effect didn’t end there, his newly announced 25% US auto import tariffs  also wrought havoc on global markets, with Tesla, among other carma","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-128501522-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/GettyImages-128501522-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/news/closing-bell-tech-tumble-and-trump-tariffs-trample-thursday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4139","ALD","OPT"],"gpt_icon":0},{"id":"2522343337","title":"TSMC’s big US bet and China’s chip tool challenger","url":"https://stock-news.laohu8.com/highlight/detail?id=2522343337","media":"Financial Times","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522343337?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:30","pubTimestamp":1743060626,"startTime":"0","endTime":"0","summary":"This is Lauly, saying hi from the warm weather in Taipei.I can’t believe it’s already been weeks since I returned from Barcelona covering the annual Mobile World Congress, one of the biggest tech exhibitions in a year. As my colleague Annie Cheng Ting-Fang mentioned in her newsletter, we had to take cold showers for three nights at our hotel due to a plumbing issue, walked more than 10,000 steps at the expo and then had to endure subway disruptions for two straight days.Taiwan, which boasts the second-largest semiconductor industry in the world, has long taken a measure of comfort in its “Silicon Shield”, the concept that its crown jewel chip economy makes it too important for the US not to defend it should China ever invade. But what if the shie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tsmc-big-us-bet-china-073026026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861127337.USD","NVIW.SI","LU0308772762.SGD","LU0861579265.USD","LU2236285917.USD","LU2191332357.HKD","SNVD.UK","LU2471134796.USD","LU2250418816.HKD","LU0096364046.USD","ALD","LU1316542783.SGD","LU1923623000.USD","NVDX","LU0225283273.USD","LU0320765059.SGD","2NVD.UK","LU0234572021.USD","LU2097344431.USD","LU1923622614.USD","LU2125909593.SGD","NVDL","NVDY","SG9999015952.SGD","LU1066051811.HKD","LU1791710582.SGD","IE00B19Z8W00.USD","NVDS.UK","LU0724617625.USD","NVDA","NVDU","NVD","NVD3.UK","LU2125154778.USD","LU1868836591.USD","LU0345768153.USD","LU2063271972.USD","IE00B5949003.HKD","FT","SG9999014575.USD","NVDD","LU2756315664.SGD","LU0511384066.AUD","NVD2.UK","IE00BN29S564.USD","LU0417517546.SGD","3NVD.UK","LU0061474960.USD","LU0868494708.USD","NVDS"],"gpt_icon":1},{"id":"2522835349","title":"DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522835349","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522835349?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":"Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025. Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis . CUPERTINO, Calif., March 26, 2025 /PRNewswire/ --DURECT Corporation  today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.Results from the AHFIRM Phase 2b trial were published in NEJM Evidence in January 2025. In addition to highlighting the key findings from this study, the article also included new trial data, including subgroup analyses that explain regional differences in patient populations and in AH treatment regimens. Variations in time from hospitalization to first dose highlighted the importance of timely treatment in patients with severe AH. The full article can be accessed here. Top line d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/durect-corporation-reports-fourth-quarter-200500269.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/durect-corporation-reports-fourth-quarter-200500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALD","DRRX","BK4557","BK4007"],"gpt_icon":0},{"id":"2521940494","title":"Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521940494","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521940494?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:45","pubTimestamp":1742503500,"startTime":"0","endTime":"0","summary":"Hypertrophic cardiomyopathy  is the most common human genetic cardiac disorder and can lead to serious complications including heart failure and sudden cardiac death. The preclinical study was financed through a grant by DZHK1 and conducted at the TUM University Hospital German Heart Center under a research collaboration2 between Poxel and the TUM University Hospital German Heart Center. Prof. Dr. Cordula Wolf, Director of the Center for Rare Congenital Heart Diseases at the TUM University Hospital German Heart Center, added: \"The findings of the pre-clinical study conducted in collaboration with Poxel represent a major step in the development of a novel therapeutic approach to treat hypertrophic cardiomyopathy, a severe and progressive disease that can lead to life-threatening cardiac events. Results obtained during this preclinical study showed that PXL065 may have the potential to improve the clinical outcomes for patients suffering from this genetic condition by reducing left ventr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poxel-announces-positive-results-preclinical-204500666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","PXXLF","LU0266512127.USD","LU0368265418.SGD","LU0788109394.HKD","LU0300736492.USD","HCM","LU0456854461.SGD","BK4588","LU0122376428.USD","BK4139","LU0300736062.USD","IE00BSNM7G36.USD","ALD","BK4138","MPC","LU0170899867.USD","BK4531","BK4585"],"gpt_icon":0},{"id":"2520992675","title":"Ampol Limited (ASX:ALD) is favoured by institutional owners who hold 51% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2520992675","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520992675?lang=en_us&edition=fundamental","pubTime":"2025-03-19 11:25","pubTimestamp":1742354724,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Ampol implies that they have significant influence over the company's share price. 48% of the business is held by the top 25 shareholders. Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business. If you want to know who really controls Ampol Limited , then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 51% to be precise, is institutions. In other words, the group stands to gain the most  from their investment into the company.Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.Let's take a closer look to see what the different types of shareholders can tell us about Ampol.The definition of compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ampol-limited-asx-ald-favoured-032524670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ALD","BK7065","ALD.AU"],"gpt_icon":0},{"id":"2514862721","title":"Ampol's (ASX:ALD) Shareholders Will Receive A Smaller Dividend Than Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862721","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514862721?lang=en_us&edition=fundamental","pubTime":"2025-02-27 04:20","pubTimestamp":1740601254,"startTime":"0","endTime":"0","summary":"Ampol Limited's  dividend is being reduced from last year's payment covering the same period to A$0.05 on the 3rd of April. This payment takes the dividend yield to 2.5%, which only provides a modest boost to overall returns.Ampol's Projected Earnings Seem Likely To Cover Future Distributions. If it is predictable over a long period, even low dividend yields can be attractive. Based on the last payment, the company wasn't making enough to cover what it was paying to shareholders. Without profits and cash flows increasing, it would be difficult for the company to continue paying the dividend at this level.Analysts expect a massive rise in earnings per share in the next year. If recent patterns in the dividend continue, we could see the payout ratio reaching 27% which is fairly sustainable.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ampols-asx-ald-shareholders-receive-202054234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ALD.AU","ALD","BK7065"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-19","symbol":"ALD","amount":0.075,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1550552400000},{"market":"US","date":"2019-01-22","symbol":"ALD","amount":0.095,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1548133200000},{"market":"US","date":"2018-12-24","symbol":"ALD","amount":0.1,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1545627600000},{"market":"US","date":"2018-11-20","symbol":"ALD","amount":0.1,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1542690000000},{"market":"US","date":"2018-10-23","symbol":"ALD","amount":0.09,"name":"联合资本","currency":"USD","type":"dividend","dateTimestamp":1540267200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALD\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-23","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-02-17","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-03-27","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-05-22","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"},{"executeDate":"2017-06-26","recordDate":null,"paymentDate":null,"value":0.065,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALD\",market:\"US\",delay:false,,,undefined,":{}}}